Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 901–1,000 of 1,015
Galbanic acid inhibits HIF-1α expression via EGFR/HIF-1α pathway in cancer cells
Eskandani, M., Abdolalizadeh, J., Hamishehkar, H., Nazemiyeh, H., & Barar, J. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.12.003 · Cited by 59
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Ahmad, J., Akhter, S., Khan, M. A., Wahajuddin, M., Greig, N. H., Kamal, M. A., Midoux, P., & Pichon, C. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160617112111 · Cited by 61
“Smart” Nanoprobes for Visualization of Tumor Microenvironments
Ma, T., Zhang, P., Hou, Y., Ning, H., Wang, Z., Huang, J., & Gao, M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800391 · Cited by 58
Advanced nanomaterials targeting hypoxia to enhance radiotherapy
Li, J., Shang, W., Li, Y., Fu, S., Tian, J., & Lu, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s173914 · Cited by 58
Naphthalimides in fluorescent imaging of tumor hypoxia – An up-to-date review
KUMARI, R. R., Sunil, D., & Ningthoujam, R. S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102979 · Cited by 57
Wang, K., Tu, Y., Wang, Y., Zong, Q., Xiao, X., Yang, R., Jiang, X., & Yuan, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21525 · Cited by 57
Ryan, L. S., Gerberich, J., Cao, J. X., An, W., Jenkins, B. A., Mason, R. P., & Lippert, A. R. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00360 · Cited by 57
She, D., Huang, H., Li, J., Peng, S., Wang, H., & Yu, X. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127359 · Cited by 56
Small-molecule probes for fluorescent detection of cellular hypoxia-related nitroreductase
Qiao, J., Wang, M., Cui, M., Fang, Y., Li, H., Zheng, C., Li, Z., Xu, Y., Hua, H., & Li, D. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114199 · Cited by 62
Alharbi, M. G., Lai, A., Sharma, S., Croft, P. K., Godbole, N., Campos, A. V., Guanzon, D., Salas-Burgos, A., Carrión, F., Zuñiga, F. A., et al. (2021) · Cancers · doi:10.3390/cancers13143388 · Cited by 60
Membrane-Activated Fluorescent Probe for High-Fidelity Imaging of Mitochondrial Membrane Potential
Lin, B., Liu, Y., Zhang, X., Fan, L., Shu, Y., & Wang, J. (2021) · ACS Sensors · doi:10.1021/acssensors.1c01390 · Cited by 56
A self-charging salt water battery for antitumor therapy
Huang, J., Yu, P., Liao, M., Dong, X., Xu, J., Ming, J., Bin, D., Wang, Y., Zhang, F., & Xia, Y. (2023) · Science Advances · doi:10.1126/sciadv.adf3992 · Cited by 56
Hypoxia-regulated gene network in drug resistance and cancer progression
Lin, S.-C., Liao, W.-L., Lee, J., & Tsai, S. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214532755 · Cited by 61
Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent
Sukhatme, V. V., Bouche, G., Meheus, L., Sukhatme, V. P., & Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.568 · Cited by 60
Metal Stable Isotopes in the Human Body: A Tribute of Geochemistry to Medicine
Albarède, F. (2015) · Elements · doi:10.2113/gselements.11.4.265 · Cited by 58
Qi, X., Xu, W., Xie, J., Wang, Y., Han, S., Wei, Z., Ni, Y., Dong, Y., & Han, W. (2016) · Scientific Reports · doi:10.1038/srep35788 · Cited by 65
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells
Meehan, J., Ward, C., Turnbull, A., Wills, J. C., Finch, A. J., Jarman, E. J., Xintaropoulou, C., Martínez-Pérez, C., Gray, M., Pearson, M. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17143 · Cited by 61
H2O2-responsive theranostic nanomedicine
Yu, L., Chen, Y., & Chen, H. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.05.023 · Cited by 57
Iikuni, S., Ono, M., Watanabe, H., Shimizu, Y., Sano, K., & Saji, H. (2018) · Theranostics · doi:10.7150/thno.20982 · Cited by 56
Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics
Bartmann, L., Schumacher, D., von Stillfried, S. F., Sternkopf, M., Alampour‐Rajabi, S., van Zandvoort, M. A. M. J., Kiessling, F. M., & Wu, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00079 · Cited by 61
Oxygen Sensing, Homeostasis, and Disease
Bels, D. D., Corazza, F., & Balestra, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1110602
Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
Sameni, M., Tovar, E. A., Essenburg, C. J., Chalasani, A., Linklater, E. S., Borgman, A. S., Cherba, D., Anbalagan, A., Winn, M. E., Graveel, C. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0187 · Cited by 58
Li, X., Liu, X., Xu, Y., Liu, J., Xie, M., Wang, N., & Chen, S. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2544 · Cited by 57
ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis
Martinengo, C., Poggio, T., Menotti, M., Scalzo, M. S., Mastini, C., Ambrogio, C., Pellegrino, E., Riera, L., Piva, R., Ribatti, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0268 · Cited by 60
Tawk, B., Schwager, C., Deffaa, O. J., Dyckhoff, G., Warta, R., Linge, A., Krause, M., Weichert, W., Baumann, M. A., Herold‐Mende, C. C., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.11.027 · Cited by 60
Lau, J., Zhang, Z., Jenni, S., Kuo, H., Liu, Z., Vullo, D., Supuran, C. T., Lin, K., & Bénard, F. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00934 · Cited by 55
TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers
Leithner, K., Hirschmugl, B., Li, Y., Tang, B., Papp, R., Nagaraj, C., Stacher, E., Stiegler, P., Lindenmann, J., Olschewski, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157453 · Cited by 60
Jahangir, S., Hosseini, S., Mostafaei, F., Sayahpour, F. A., & Eslaminejad, M. B. (2018) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-018-6202-x · Cited by 58
Hong, X., Zhong, L., Xie, Y., Zheng, K., Pang, J., Li, Y., Yang, Y., Xu, X., Mi, P., Cao, H., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01437 · Cited by 60
Membranous NOX5-derived ROS oxidizes and activates local Src to promote malignancy of tumor cells
Chen, J., Wang, Y., Zhang, W., Zhao, D., Zhang, L., Fan, J., Li, J., & Zhan, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0193-z · Cited by 56
Inhibition of tumour cell growth by carnosine: some possible mechanisms
Hipkiss, A. R., & Gaunitz, F. (2013) · Amino Acids · doi:10.1007/s00726-013-1627-5 · Cited by 58
[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models
Peeters, S. G. J. A., Dubois, L. J., Lieuwes, N. G., Laan, D., Mooijer, M. P. J., Schuit, R. C., Vullo, D., Supuran, C. T., Eriksson, J., Windhorst, A. D., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0831-y · Cited by 54
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
Foehrenbacher, A., Patel, K., Abbattista, M. R., Guise, C. P., Secomb, T. W., Wilson, W. R., & Hicks, K. O. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00263 · Cited by 54
Self-citationHaldorsen, I. S., Stefansson, I. M., Grüner, R., Husby, J. A., Magnussen, I. J., Werner, H. M. J., Salvesen, Ø. O., Bjørge, L., Trovik, J., Taxt, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.694 · Cited by 60
Targeting Tumor Hypoxia With Hypoxia-Activated Prodrugs
Yeh, J. J., & Kim, W. Y. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0759 · Cited by 61
Zhou, X., & Lei, Q. (2016) · Protein & Cell · doi:10.1007/s13238-016-0288-z · Cited by 57
Janonienė, A., Liu, Z., Baranauskienė, L., Mäkilä, E. M., Ma, M., Salonen, J., Hirvonen, J. J., Zhang, H., Petrikaitė, V., & Santos, H. A. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b04038 · Cited by 56
Advances in Stimulus‐Responsive Polymeric Materials for Systemic Delivery of Nucleic Acids
Sun, M., Wang, K., & Oupický, D. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201701070 · Cited by 60
Ivanova, I. G., Park, C. V., Yemm, A. I., & Kenneth, N. S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky127 · Cited by 53
Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as
Pantziarka, P., Sukhatme, V. V., Crispino, S., Bouche, G., Meheus, L., & Sukhatme, V. P. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.824 · Cited by 54
Ding, N., Li, Z., Tian, X., Zhang, J., Guo, K., & Wang, P. (2019) · Chemical Communications · doi:10.1039/c9cc06727b · Cited by 54
Liu, Z., Xue, Y., Wu, M., Yang, G., Lan, M., & Zhang, W. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01368 · Cited by 54
Koens, R., Tabata, Y., Serrano, J. C., Aratake, S., Yoshino, D., Kamm, R. D., & Funamoto, K. (2020) · APL Bioengineering · doi:10.1063/1.5127069 · Cited by 53
Izadi, S., Moslehi, A., Kheiry, H., Kiani, F. K., Ahmadi, A., Masjedi, A., Ghani, S., Rafiee, B., Karpisheh, V., Hajizadeh, F., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02892-y · Cited by 53
RetractedZhang, Z., Fan, J., Du, J., & Peng, X. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213575 · Cited by 53
The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT
Moon, E. J., Petersson, K., & Olcina, M. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1988178 · Cited by 63
Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases
Talekar, M., Tran, T.-H., & Amiji, M. M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9772-2 · Cited by 56
Peng, W., Xiong, E., Ge, L., Wan, Y.-Y., Zhang, C., Du, F., Xu, M., Bhat, R. A., Jin, J., & Gong, A. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.12.006 · Cited by 54
Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Alimoradi, H., Matikonda, S. S., Gamble, A. B., Giles, G. I., & Greish, K. F. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160217130049 · Cited by 57
Kim, H. S., Sharma, A. K., Ren, W. X., Han, J., & Kim, J. S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.006 · Cited by 54
Huang, S., Qi, P., Zhang, T., Li, F., & He, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6929 · Cited by 62
Karges, J., Kuang, S., Ong, Y. C., Chao, H., & Gasser, G. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202003486 · Cited by 54
Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment
Jackson, N., Cecchi, D., Beckham, W., & Chithrani, D. B. (2024) · Molecules · doi:10.3390/molecules29112438 · Cited by 52
“For example, the tumor microenvironment can become hypoxic, increasing the resistance of tumors to radiotherapy treatment [6].”
BackgroundWang, D., Shi, R., Zhou, J., Shi, S., Wu, H., Xu, P., Wang, H., Xia, G., Barnhart, T. E., Cai, W., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.005 · Cited by 54
Identifying metabolic limitations in the tumor microenvironment
Cognet, G., & Muir, A. (2024) · Science Advances · doi:10.1126/sciadv.adq7305 · Cited by 72
Klaassen, R., Bennink, R. J., van Tienhoven, G., Bijlsma, M. F., Besselink, M. G., Henegouwen, M. I. V. B., Wilmink, J. W., Nederveen, A. J., Windhorst, A. D., Hulshof, M. C. C. M., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.05.009 · Cited by 54
Systemic Delivery of SapC-DOPS Has Antiangiogenic and Antitumor Effects Against Glioblastoma
Wojton, J., Chu, Z., Mathsyaraja, H., Meisen, W. H., Denton, N. L., Kwon, C.-H., Chow, L. M. L., Palascak, M. B., Franco, R. S., Bourdeau, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.114 · Cited by 55
Saggar, J. K., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2298 · Cited by 52
Yang, X., Li, S., Li, W., Chen, J., Xiao, X., Wang, Y., Yan, G., & Chen, L. (2012) · Oncology Reports · doi:10.3892/or.2012.2146 · Cited by 55
Choudhury, S., Bhootada, Y., Gorbatyuk, O. S., & Gorbatyuk, M. S. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.34 · Cited by 58
Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx)
Chaudary, N., Pintilie, M., Schwock, J., Dhani, N. C., Clarke, B. A., Milosevic, M., Fyles, A., & Hill, R. P. (2012) · Cancers · doi:10.3390/cancers4030821 · Cited by 62
Silvers, W. C., Payne, A. S., & McCarley, R. L. (2011) · Chemical Communications · doi:10.1039/c1cc14578a · Cited by 52
Chan, N. H. L., Ali, M., McCallum, G. P., Kumareswaran, R., Koritzinsky, M., Wouters, B. G., Wells, P. G., Gallinger, S., & Bristow, R. G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0246 · Cited by 53
Lecavalier‐Barsoum, M., Chaudary, N., Han, K. C.-Z., Koritzinsky, M., Hill, R. P., & Milosevic, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31297 · Cited by 55
Delivering Functional Imaging on the MRI-Linac: Current Challenges and Potential Solutions
Datta, A., Aznar, M. C., Dubec, M. J., Parker, G. J. M., & O’Connor, J. P. B. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.08.005 · Cited by 52
Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
Sanduleanu, S., van der Wiel, A. M.-M. A., Lieverse, R. I. Y., Marcus, D., Ibrahim, A., Primakov, S. P., Wu, G., Theys, J., Yaromina, A., Dubois, L. J., et al. (2020) · Cancers · doi:10.3390/cancers12051322 · Cited by 56
Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
Tang, W., & Zhao, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115235 · Cited by 50
Jiang, L., Bai, H., Liu, L., Lv, F., Ren, X., & Wang, S. (2019) · Angewandte Chemie · doi:10.1002/ange.201905884 · Cited by 51
Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges
Hu, X., Zhang, Y.-S., Liu, Y., Wang, N., Zeng, X., & Zhang, L. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01637-w · Cited by 46
Cleavable collagenase-assistant nanosonosensitizer for tumor penetration and sonodynamic therapy
Yin, T., Chen, H., Ma, A.-Q., Pan, H., Chen, Z., Tang, X., Huang, G., Liao, J., Zhang, B., Zheng, M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121992 · Cited by 53
Bioresponsive Immunotherapeutic Materials
Han, J., Sheng, T., Zhang, Y., Cheng, H., Gao, J., Yu, J., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202209778 · Cited by 62
Nanomaterials-Involved Tumor-Associated Macrophages’ Reprogramming for Antitumor Therapy
Li, S., Hou, H., Chu, X., Zhu, Y., Zhang, Y., Duan, M., Liu, J., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c12387 · Cited by 56
Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents
Montero, V., Montana, M., Carré, M., & Vanelle, P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116360 · Cited by 54
Metran-Nascente, C., Yeung, I. W. T., Vines, D. C., Metser, U., Dhani, N. C., Green, D., Milosevic, M., Jaffray, D. A., & Hedley, D. W. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167650 · Cited by 54
Hayano, K., Tian, F., Kambadakone, A. R., Yoon, S. S., Duda, D. G., Ganeshan, B., & Sahani, D. V. (2015) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000239 · Cited by 51
Ma, J., Mi, C., Wang, K. S., Lee, J. J., & Jin, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9070 · Cited by 58
A Tumor Vascular‐Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia
Luan, X., Guan, Y., Liu, H., Lu, Q., Zhao, M., Sun, D., Lovell, J. F., Sun, P., Chen, H., & Fang, C. (2018) · Advanced Science · doi:10.1002/advs.201800034 · Cited by 50
Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis
Bousseau, S., Vergori, L., Soleti, R., Lenaers, G., Martínez, M. C., & Andriantsitohaina, R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.003 · Cited by 53
Exosomes: New insights into cancer mechanisms
Sahebi, R., Langari, H., Fathinezhad, Z., Sani, Z. B., Avan, A., Ghayour‐Mobarhan, M., & Rezayi, M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29120 · Cited by 53
Shen, H. M., Cook, K. M., Gee, H. E., & Hau, E. K. C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01639-2 · Cited by 58
Cheng, X., Li, H., Ge, X., Chen, L., Liu, Y., Mao, W., Zhao, B., & Yuan, W. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.576420 · Cited by 51
Nanotechnology Tools Enabling Biological Discovery
Salvador-Morales, C., & Grodzinski, P. A. (2022) · ACS Nano · doi:10.1021/acsnano.1c10635 · Cited by 57
In Vivo Nitroreductase Imaging via Fluorescence and Chemical Shift Dependent 19F NMR
Chen, S., Xiao, L. X., Li, Y., Qiu, M., Yuan, Y., Zhou, R., Li, C., Zhang, L., Jiang, Z., Liu, M., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202213495 · Cited by 67
Manoharan, D., Wang, L., Chen, Y., Li, W., & Yeh, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400746 · Cited by 52
Hefny, S. M., El-Moselhy, T. F., El-Din, N. S., Ammara, A., Angeli, A., Ferraroni, M., El‐Dessouki, A. M., Shaldam, M. A., Yahya, G., Al-Karmalawy, A. A., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116527 · Cited by 50
Heterogeneity of glycolysis in cancers and therapeutic opportunities
Warmoes, M. O., & Locasale, J. W. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.019 · Cited by 55
Mitra, K. (2016) · Dalton Transactions · doi:10.1039/c6dt03665a · Cited by 50
Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review
Yamakawa, M., Doh, S. J., Santosa, S. M., Montana, M., Qin, E. C., Kong, H., Han, K., Yu, C. Q., Rosenblatt, M. I., Kazlauskas, A., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21496 · Cited by 53
Chen, H., Bi, Q., Yao, Y., & Tan, N. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00665b · Cited by 50
Anari, F., Ramamurthy, C., & Zibelman, M. (2018) · Future Oncology · doi:10.2217/fon-2017-0585 · Cited by 50
Huang, C., Lowerison, M. R., Lucien, F., Gong, P., Wang, D., Song, P., & Chen, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41373-0 · Cited by 53
P4HB, a Novel Hypoxia Target Gene Related to Gastric Cancer Invasion and Metastasis
Zhang, J., Guo, S., Wu, Y., Zheng, Z., Wang, Y., & Zhao, Y. (2019) · BioMed Research International · doi:10.1155/2019/9749751 · Cited by 62
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
Advanced nanomaterials for hypoxia tumor therapy: challenges and solutions
Sundaram, A., Peng, L., Chai, L., Xie, Z., Ponraj, J. S., Wang, X., Wang, G., Zhang, B., Nie, G., Xie, N., et al. (2020) · Nanoscale · doi:10.1039/d0nr06271e · Cited by 50
Voissiere, A., Jouberton, E., Maubert, E., Degoul, F., Peyrode, C., Chezal, J.-M., & Miot-Noirault, É. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181340 · Cited by 49
Han, J., Hyun, J., Park, J., Jung, S., Oh, Y., Kim, Y., Ryu, S.-H., Kim, S., Jeong, E. I., Jo, D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110102 · Cited by 51
Zhuang, J., Liu, S., Li, B., Li, Z., Wu, C., Xu, D., Pan, W., Li, Z., Liu, X., & Liu, B. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202420643 · Cited by 52
Ultrasound‐Activated Theranostic Materials and Their Bioapplications
Zhu, K., Wang, J., Wang, Z., Chen, Q., Song, J., & Chen, X. S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202422278 · Cited by 53
Therapeutic gene modified cell based cancer vaccines
Kozłowska, A. K., Mackiewicz, J., & Mackiewicz, A. A. (2013) · Gene · doi:10.1016/j.gene.2013.03.056 · Cited by 52
The glioblastoma vasculature as a target for cancer therapy
Dimberg, A. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140278 · Cited by 52
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.